AIM ImmunoTech (NYSE:AIM – Free Report) had its price objective lowered by Maxim Group from $2.00 to $1.00 in a report released on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.
Separately, Ascendiant Capital Markets decreased their price objective on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.
AIM ImmunoTech Price Performance
AIM ImmunoTech (NYSE:AIM – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) EPS for the quarter. The company had revenue of $0.05 million during the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%. On average, analysts anticipate that AIM ImmunoTech will post -0.35 EPS for the current year.
Institutional Investors Weigh In On AIM ImmunoTech
A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC acquired a new stake in AIM ImmunoTech Inc. (NYSE:AIM – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is owned by institutional investors and hedge funds.
About AIM ImmunoTech
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Recommended Stories
- Five stocks we like better than AIM ImmunoTech
- Short Selling: How to Short a Stock
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Most Volatile Stocks, What Investors Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.